alendronate has been researched along with Furcation Defects in 8 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Furcation Defects: Conditions in which a bifurcation or trifurcation of the molar tooth root becomes denuded as a result of periodontal disease. It may be followed by tooth mobility, temperature sensitivity, pain, and alveolar bone resorption.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the impact of alendronate (ALD) and estrogen (EST) therapies and their withdrawal on bone loss in experimental periodontitis in ovariectomized rats." | 7.72 | Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. ( Casati, MZ; de Assis, DR; Duarte, PM; Nociti, FH; Sallum, AW; Sallum, EA, 2004) |
| "Alendronate (ALN) has antiresorptive and osteostimulative properties." | 6.87 | One percent alendronate and aloe vera gel local host modulating agents in chronic periodontitis patients with class II furcation defects: A randomized, controlled clinical trial. ( Dileep, P; Ipshita, S; Kumar, S; Kurian, IG; Pradeep, AR; Singh, P, 2018) |
| " Superior clinical treatment outcomes were shown when alendronate, rosuvastatin, boric acid, simvastatin, and tetracycline (only at 3 months) were utilized in furcation defects in conjunction with SRP alone or SRP + placebo." | 5.41 | Local drug delivery in the treatment of furcation defects in periodontitis: a systematic review. ( Chatzopoulos, GS; Koidou, VP; Tsalikis, L, 2023) |
| "The aim of this study was to evaluate the impact of alendronate (ALD) and estrogen (EST) therapies and their withdrawal on bone loss in experimental periodontitis in ovariectomized rats." | 3.72 | Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats. ( Casati, MZ; de Assis, DR; Duarte, PM; Nociti, FH; Sallum, AW; Sallum, EA, 2004) |
| "Alendronate (ALN) has antiresorptive and osteostimulative properties." | 2.87 | One percent alendronate and aloe vera gel local host modulating agents in chronic periodontitis patients with class II furcation defects: A randomized, controlled clinical trial. ( Dileep, P; Ipshita, S; Kumar, S; Kurian, IG; Pradeep, AR; Singh, P, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chatzopoulos, GS | 1 |
| Koidou, VP | 1 |
| Tsalikis, L | 1 |
| Ipshita, S | 1 |
| Kurian, IG | 1 |
| Dileep, P | 1 |
| Kumar, S | 1 |
| Singh, P | 1 |
| Pradeep, AR | 4 |
| Wanikar, I | 1 |
| Rathod, S | 1 |
| Kolte, AP | 1 |
| Kumari, M | 2 |
| Rao, NS | 2 |
| Naik, SB | 2 |
| Pulikkotil, SJ | 1 |
| Nath, S | 1 |
| Kanoriya, D | 1 |
| Garg, V | 1 |
| Singhal, S | 1 |
| Duarte, PM | 1 |
| de Assis, DR | 1 |
| Casati, MZ | 1 |
| Sallum, AW | 1 |
| Sallum, EA | 1 |
| Nociti, FH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet Rich Fibrin Combined With 1% Alendronate Gel in Treatment of Mandibular Degree II Furcation Defects: A Randomized Controlled Clinical Trial[NCT02609061] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alendronate and Furcation Defects
| Article | Year |
|---|---|
Local drug delivery in the treatment of furcation defects in periodontitis: a systematic review.
Topics: Alendronate; Dental Scaling; Furcation Defects; Humans; Periodontitis; Root Planing; Rosuvastatin Ca | 2023 |
4 trials available for alendronate and Furcation Defects
| Article | Year |
|---|---|
One percent alendronate and aloe vera gel local host modulating agents in chronic periodontitis patients with class II furcation defects: A randomized, controlled clinical trial.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Chronic Periodontitis; Dental Scaling; Female; | 2018 |
Clinico-radiographic evaluation of 1% alendronate gel as an adjunct and smart blood derivative platelet rich fibrin in grade II furcation defects.
Topics: Alendronate; Furcation Defects; Humans; Molar; Periodontal Index; Platelet-Rich Fibrin | 2019 |
Mandibular Degree II Furcation Defects Treatment With Platelet-Rich Fibrin and 1% Alendronate Gel Combination: A Randomized Controlled Clinical Trial.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Combined Modality Therapy; Dental Plaque Index | 2017 |
1% alendronate gel as local drug delivery in the treatment of Class II furcation defects: a randomized controlled clinical trial.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Bone Regeneration; Chi-Square Distribution; De | 2013 |
3 other studies available for alendronate and Furcation Defects
| Article | Year |
|---|---|
Letter to the editor: authors' response.
Topics: Alendronate; Bone Density Conservation Agents; Drug Delivery Systems; Female; Furcation Defects; Hum | 2014 |
Letter to the Editor: re: 1% alendronate gel as local drug delivery in the treatment of class II furcation defects: a randomized controlled clinical trial.
Topics: Alendronate; Bone Density Conservation Agents; Drug Delivery Systems; Female; Furcation Defects; Hum | 2014 |
Alendronate may protect against increased periodontitis-related bone loss in estrogen-deficient rats.
Topics: Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Alveolar Process; Animals; Dental Plaque Inde | 2004 |